Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Rhea-AI Summary

Cuprina Holdings (Nasdaq: CUPR) received a Nasdaq noncompliance notice dated November 26, 2025 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2).

Cuprina has an initial 180-calendar-day compliance period to regain the $1.00 closing bid for at least ten consecutive business days. If not regained, the company may be eligible for a second 180-day period by meeting market value and other initial listing standards (excluding the bid price) and providing written notice to cure, potentially by effecting a reverse stock split. Shares will continue to trade uninterrupted under the symbol CUPR while the process unfolds. Cuprina is evaluating options to regain compliance but stated there is no assurance it will do so.

Positive

• Nasdaq notice dated Nov 26, 2025
• Initial 180-calendar-day compliance period
• Requirement: $1.00 closing bid for 10 consecutive business days
• Shares continue trading under CUPR

Negative

• Currently noncompliant with Nasdaq $1.00 minimum bid
• Risk of delisting if deficiency is not cured within compliance periods
• May need a reverse stock split to regain compliance
• Company states no assurance it will regain compliance

News Market Reaction

+1.47%

1 alert

+1.47% News Effect

+$206K Valuation Impact

$14M Market Cap

0.4x Rel. Volume

On the day this news was published, CUPR gained 1.47%, reflecting a mild positive market reaction. This price movement added approximately $206K to the company's valuation, bringing the market cap to $14M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Minimum bid requirement: $1 per share Noncompliance window: 30 business days Initial compliance period: 180 calendar days +5 more

8 metrics

Minimum bid requirement $1 per share Nasdaq Listing Rule 5550(a)(2) continued listing standard

Noncompliance window 30 business days Period of sub-$1 closing bid triggering Nasdaq notice

Initial compliance period 180 calendar days Time allowed to regain Nasdaq minimum bid compliance

Required compliant streak 10 business days Minimum stretch with ≥$1 closing bid to cure deficiency

Additional compliance period 180 calendar days Potential second period if other Nasdaq standards are met

Current share price $0.495 Before publication of Nasdaq deficiency notice release

52-week high $9.50 Pre-news 52-week peak price level

52-week low $0.55 Pre-news 52-week low compared with current price below this level

Market Reality Check

Price: $0.4346 Vol: Volume 161,836 is 2.1x th...

high vol

$0.4346 Last Close

Volume Volume 161,836 is 2.1x the 20-day average of 77,204, indicating elevated trading interest ahead of the notice. high

Technical Shares at $0.495 are trading well below the 200-day MA of $3.57 and under the $1 Nasdaq minimum bid.

Peers on Argus

CUPR’s move contrasted with mixed peers: same-industry names showed moves from -...

1 Down

CUPR’s move contrasted with mixed peers: same-industry names showed moves from -4.23% (HBIO) to +13.58% (NXGL). Momentum scanner flagged NXGL at -4.89% with no news, suggesting CUPR’s trading was more company-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 09 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Earnings & outlook	Negative	-6.6%	Weak revenue and net loss with 2026 initiatives outlined.
Nov 28	Listing compliance	Negative	+1.5%	Nasdaq notice for failing to meet $1.00 minimum bid requirement.
Nov 18	Strategic partnership	Positive	-0.0%	Joint venture for novel iodine-based antiseptic wound care products.
Oct 27	Strategic MOU	Positive	+19.1%	MOU to integrate medical waste recycling into a Singapore facility.
Oct 06	Investor presentation	Neutral	-3.6%	Announcement of participation in Skyline Signature Series investor event.

Pattern Detected

News and strategic updates have produced mixed reactions; operational partnerships sometimes drew strong buying, while regulatory and earnings items often met selling or muted responses.

Recent Company History

Over the last few months, Cuprina reported weak financials, with $18,040 in revenue and a $1,528,121 net loss for the six months ended June 30, 2025, and outlined 2026 growth plans. It formed a joint venture for iodine-based wound care and signed an MOU on medical waste technology. Governance changes included an auditor switch and management turnover. The Nasdaq minimum bid deficiency notice on November 26, 2025 now adds listing-compliance risk to this trajectory.

Market Pulse Summary

This announcement formally documented that Cuprina’s shares fell below Nasdaq’s $1 minimum bid for 3...

Analysis

This announcement formally documented that Cuprina’s shares fell below Nasdaq’s $1 minimum bid for 30 consecutive business days, triggering a 180-day window to regain compliance, with a possible second 180-day period. It follows recent weak financial results and strategic initiatives, adding listing-compliance risk to the story. Investors may track progress toward the ten-day ≥$1 requirement and any actions, such as a potential reverse stock split, to address the deficiency.

Key Terms

nasdaq listing rules 5550(a)(2), minimum bid price, nasdaq capital market, reverse stock split, +1 more

5 terms

nasdaq listing rules 5550(a)(2) regulatory

"under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price"

Nasdaq Listing Rule 5550(a)(2) is a Nasdaq Capital Market standard that sets a minimum share-price requirement companies must meet to list their common stock on that market. Think of it as a minimum entrance score for a club: if a stock trades below the required price, the company can face warnings or removal, which matters to investors because it affects liquidity, tradability and perceptions of company stability.

minimum bid price financial

"to maintain a minimum bid price of $1 per share"

The minimum bid price is the lowest share price that a market, regulator, or specific offering will accept for a trade, listing, or auction—think of it as a reserve or floor that a stock must meet to qualify for certain actions. It matters to investors because falling below that floor can limit trading options, trigger compliance measures or delisting risks, and affect liquidity and the perceived value of a holding, much like a reserve price in an auction sets the baseline for a sale.

nasdaq capital market regulatory

"initial listing standards for The Nasdaq Capital Market, with the exception"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

reverse stock split financial

"intention to cure the deficiency during the second compliance period, by effecting a reverse stock split"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

delisting regulatory

"Nasdaq will provide notice that its securities will be subject to delisting."

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

AI-generated analysis. Not financial advice.

SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina’s closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide Cuprina with written confirmation of compliance and this matter will be closed.

In the event the Company does not regain compliance, Cuprina may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Cuprina meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.

The Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares, and the shares will continue to trade uninterrupted under the symbol "CUPR." 

Cuprina is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although Cuprina will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com. 

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5^th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com

FAQ

What did Cuprina (CUPR) receive from Nasdaq on November 26, 2025?

A Nasdaq noncompliance notice for failing to meet the $1.00 minimum bid under Rule 5550(a)(2).

How long is Cuprina's initial compliance period to regain Nasdaq listing (CUPR)?

Cuprina has an initial 180-calendar-day period to regain compliance.

What price requirement must CUPR meet to regain Nasdaq compliance during the 180-day period?

A closing bid of at least $1.00 for a minimum of 10 consecutive business days.

Will Cuprina (CUPR) be delisted immediately after the Nasdaq notice?

No. The notice does not cause immediate delisting and shares will continue trading under CUPR.

What can Cuprina do if it fails to regain compliance in the first 180 days?

It may seek an additional 180-calendar-day period by meeting market value and other initial listing standards and notifying Nasdaq, potentially via a reverse stock split.

Does Cuprina guarantee it will regain Nasdaq compliance (CUPR)?

No. The company stated it will try to regain compliance but provided no assurance it will succeed.